loading page

Recurrent thymic carcinoma treated with anterior median thoracotomy, innominate vein replacement for superior vena cava, and iodide implantation: A case report and review of the literature
  • +1
  • zhong zheng Chen,
  • Wen-dong Qu,
  • Xingshu zhang,
  • Yongxiang Song
zhong zheng Chen
Affiliated Hospital of Zunyi Medical University
Author Profile
Wen-dong Qu
Affiliated Hospital of Zunyi Medical University
Author Profile
Xingshu zhang
Affiliated Hospital of Zunyi Medical University
Author Profile
Yongxiang Song
Affiliated Hospital of Zunyi Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Thymic neuroendocrine tumors are rare malignant tumors with neuroendocrine functions located in the anterior mediastinum thymic region. They exhibit a high degree of malignancy and can early invade surrounding fat,pericardium, pleura, major blood vessels, and lungs,posing a significant risk of recurrence.Here, we report a case of recurrent thymic cancer treated with complete surgical resection, replacement of the innominate vein, superior vena cava formation, and iodine ion insertion.A 51-year-old male diagnosed with stage lllA malignant thymoma in November 2021, accompanied by lymph node metastasis,involving the peripheral left lung.The patient underwent six cycles of adjuvant immunotherapy with pembrolizumab and cisplatin plus etoposide, along with one course of radiotherapy postoperatively.Subsequently, the patient received regular immunotherapy and follow-up at our hospital. In October 2023,chest CT revealed tumor recurrence, with infiltration into the pericardium, bilateral innominate veins, superior vena cava, and brachiocephalic artery.Subsequently, the patient underwent a midline thoracotomy for extensive resection of recurrent thymic tumor,enlargement of pericardial resection, left innominate vein-to-right atrial artificial grafting,superior vena cava formation,and iodine-125radioisotope brachytherapy.Aggressive surgical intervention combined with adjuvant therapy is an essential treatment modality for locally advanced thymic cancer involving the superior vena cava and surrounding blood vessels.
04 Apr 2024Submitted to Cancer Reports
05 Apr 2024Submission Checks Completed
05 Apr 2024Assigned to Editor
05 Apr 2024Review(s) Completed, Editorial Evaluation Pending
11 Apr 2024Reviewer(s) Assigned
19 Jul 2024Editorial Decision: Revise Major
15 Aug 20241st Revision Received
16 Sep 2024Submission Checks Completed
16 Sep 2024Assigned to Editor
16 Sep 2024Review(s) Completed, Editorial Evaluation Pending
25 Oct 2024Reviewer(s) Assigned